Discovery of potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor SGL5213 for type 2 diabetes treatment

Add time:07/11/2019    Source:sciencedirect.com

A new series of C-phenyl d-glucitol derivatives was designed and synthesized, and their SGLT1 inhibitory potency and absorbability were evaluated. We also investigated whether kidney drug retention could be avoided by creating molecules with different excretion pathways. To achieve a class of molecules with low absorption and that were excreted in bile, optimized synthesis was performed to bring the ClogP value and the topological polar surface area to within the appropriate ranges. Compounds 34d and 34j were poorly absorbed, but the absorbed compounds were mainly excreted in bile. Thus, smaller amounts of persistent residue in the kidneys were observed. Since 34d exerted a glucose-lowering effect at a dose of 0.3 mg/kg (p.o.) in SD rats, this compound (SGL5213) could be a clinical candidate for the treatment of type 2 diabetes.

We also recommend Trading Suppliers and Manufacturers of 2(3H)-Furanone,5-[(1S)-1-(acetyloxy)-3-methylbutyl]dihydro-4-methyl-,(4R,5R)-(9CI) (cas 828263-41-8). Pls Click Website Link as below: cas 828263-41-8 suppliers

Prev:Synthesis and thermal decomposition of rare earth isovalerates and their solutions with amines as an effective pathway to obtain oxide nanomaterials
Next:Efficient indenones synthesis via iridium-catalyzed decarboxylative annulation between 2-oxo-2-phenylacetic acids and alkynes)